Urinary Bladder DiseasesPhase 3BESIDENCT01908829
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
A Phase 3 study testing mirabegron 25 mg, mirabegron 50 mg and solifenacin 5 mg in people with Urinary Bladder Diseases and Urinary Bladder Overactive, run by Astellas Pharma Europe Ltd. at 219 sites in 31 countries.
Trial summary
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- What is being tested?
- mirabegron 25 mg, mirabegron 50 mg and solifenacin 5 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,174 participants
- Where
- 219 sitesin 31 countries
- Study dates
- 10 Jul 2013to 25 Nov 2014
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Main Inclusion at Screening:
- Subject has symptoms of OAB (urinary frequency and urgency with urgency incontinence) for >= 3 months prior to the screening visit
- Subject is willing and able to complete the micturition diary and questionnaires correctly, including collection and measurement of urine output for 3 days prior to each visit;
- Subject has symptoms of "wet" OAB (urinary frequency and urgency with incontinence or mixed incontinence with predominant urgency incontinence), and reports an average of at least 2 incontinence episodes per day.
- Main Inclusion at Run-in (Visit 2):
- Subject experiences on average at least 1 episode of urgency (grade 3 or 4) with or without incontinence per 24-hour period during the 3-day micturition diary period.
Show all 10Show fewer
- Subject experiences on average at least 2 incontinence episodes per 24-hour period during the 3-day micturition diary period.
- Subject experiences on average at least 8 micturitions (excluding incontinence episodes) per 24-hour period during the 3-day micturition diary period.
- Main Inclusion at Randomization (Visit 3):
- Subject experiences at least 1 incontinence episode during the 3-day micturition diary period and wishes to increase their treatment for OAB symptoms.
Who cannot join
- Main Exclusion at Screening:
- Subject in the opinion of the investigator has clinically significant Bladder Outlet Obstruction (BOO).
- Subject has significant Post-void residual (PVR) volume (PVR > 150 ml).
- Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the investigator
- Subject has an indwelling catheter or practices intermittent self catheterization.
- Subject has evidence of a UTI.
Show all 20Show fewer
- Subject has chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs
- Subject has moderate to severe hepatic impairment
- Subject has severe renal impairment or End Stage Renal disease
- Subject has a clinically significant abnormal Electrocardiogram (ECG)
- Subject has a concurrent malignancy or history of cancer (except noninvasive skin cancer) within the last 5 years prior to screening.
- Subject has a QTcF interval > 450 ms for males or > 470 ms for females or is at risk of QT prolongation (e.g., family history of long QT syndrome, hypokalaemia).
- Subject has received intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin.
- Subject has severe uncontrolled hypertension, which is defined as a sitting average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg.
- Main Exclusion at Randomization (visit 3):
- Subject has achieved 100% continence from Visit 2 to Visit 3 (no incontinence episodes are recorded in the 3 day diary administered for 3 days prior to Visit 3).
- Subject does not desire an increase in study medication.
- Subject has an average total daily urine volume > 3000ml as recorded in the micturition diary.
- Subject has severe uncontrolled hypertension, which is defined as a sitting average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg.
- Subject has a clinically significant abnormal ECG
Trial locations and contacts
219 sites in 31 countries.
219 sites in 31 countries
United States36 sites
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico, 87102
Alexandria Clinical Research
Alexandria, Virginia, 22304
Brooklyn Urology Research Group
Brooklyn, New York, 11215
Meridien Research
Brooksville, Florida, 33016
Associated Pharmaceutical Research Center, Inc.
Buena Park, California, 90620
PMG Research of Raleigh, dba PMG Research of Cary
Cary, North Carolina, 27518
The Urology Group
Cincinnati, Ohio, 45212
Innovative Research of West FL
Clearwater, Florida, 33756
North Idaho Urology
Coeur d'Alene, Idaho, 83814
Providence Health Partners
Dayton, Ohio, 45439
Advanced Urology Centers of New York
Garden City, New York, 11530
Alliance Urology Specialists
Greensboro, North Carolina, 27403
Best Quality Research Inc.
Hialeah, Florida, 33016
Palmetto Professional Research
Hialeah, Florida, 33016
MedStar Health Research Institute
Hyattsville, Maryland, 20782
First Urology, PSC
Jeffersonville, Indiana, 47130
The Clinical Trial Center
Jenkintown, Pennsylvania, 19046
Beyer Research
Kalamazoo, Michigan, 49009
Premier Medical Group of the Hudson Valley PC
Kingston, New York, 12401
Urology Center of Central Florida
Kissimmee, Florida, 34741
The American Institute of Research
Los Angeles, California, 90017
Deaconess Gateway Health Center
Newburgh, Indiana, 47630
Quality Clinical Research
Omaha, Nebraska, 68114
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York, 12601
Wake Research Associates LLC
Raleigh, North Carolina, 27612
Health Concepts
Rapid City, South Dakota, 57702
Jean Brown Research
Salt Lake City, Utah, 84124
Meridian Clinical Research, LLC
Savannah, Georgia, 31406
Herman Clinical Research
Suwanee, Georgia, 30024
Meridien Research
Tampa, Florida, 33606
Stedman Clinical Trials
Tampa, Florida, 33613
Genova Clinical Research
Tucson, Arizona, 85704
Bayview Research Group
Valley Village, California, 91607
Bay State Clinical Trials, Inc.
Watertown, Massachusetts, 02472
Private Practice
West Palm Beach, Florida, 33407
PMG Research of Winston-Salem, LLC
Winston-Salem, North Carolina, 27103
Russia14 sites
Site: 70003
Moscow
Site: 70004
Moscow
Site: 70005
Moscow
Site: 70008
Moscow
Site: 70010
Moscow
Site: 70011
Moscow
Site: 70012
Moscow
Site: 70024
Moscow
Site: 70013
Rostove-on-Don
Site: 70002
Saint Petersburg
Site: 70006
Saint Petersburg
Site: 70007
Saint Petersburg
Site: 70009
Saint Petersburg
Site: 70025
Saratov
Canada12 sites
Site: 15001
Barrie
Site: 15009
Bathurst
Site: 15006
Brampton
Site: 15015
Granby
Site: 15014
Kelowna
Site: 15007
Kitchener
Site: 15019
Sherbrooke
Site: 15012
Toronto
Site: 15013
Toronto
Site: 15016
Victoria
Site: 15047
Victoria
Site: 15018
Victoriaville
Spain12 sites
Site: 34012
Barcelona
Site: 34016
Bilbao
Site: 34013
Donostia / San Sebastian
Site: 34001
Getafe (Madrid)
Site: 34004
Madrid
Site: 34015
Madrid
Site: 34023
Mendaro
Site: 34021
Miranda de Ebro
Site: 34018
San Sebastián de los Reyes
Site: 34007
Seville
Site: 34020
Seville
Site: 34014
Vigo
United Kingdom12 sites
Site: 44007
Bristol
Site: 44012
Cambridge
Site: 44015
Cheltenham
Site: 44019
Coventry
Site: 44009
Garston
Site: 44016
Kings Lynn
Site: 44017
London
Site: 44018
Northampton
Site: 44010
Nottingham
Site: 44008
Plymouth
Site: 44013
Taunton
Site: 44011
West Yorkshire
Austria11 sites
Site: 43008
Graz
Site: 43001
Innsbruck
Site: 43006
Innsbruck
Site: 43007
Linz
Site: 43002
Vienna
Site: 43004
Vienna
Site: 43005
Vienna
Site: 43010
Vienna
Site: 43011
Vienna
Site: 43012
Vienna
Site: 43003
Wels
Germany11 sites
Site: 49008
Bad Ems
Site: 49022
Berlin
Site: 49003
Eisleben Lutherstadt
Site: 49021
Hagenow
Site: 49011
Halle
Site: 49004
Hamburg
Site: 49018
Henningsdorf
Site: 49009
Hettstedt
Site: 49017
Koblenz
Site: 49020
Reutlingen
Site: 49014
Sangerhausen
Czechia10 sites
Site: 42015
Brno
Site: 42020
Mělník
Site: 42018
Náchod
Site: 42004
Pilsen
Site: 42021
Pilsen
Site: 42007
Prague
Site: 42008
Prague
Site: 42016
Prague
Site: 42017
Prague
Site: 42022
Prague
Belgium8 sites
Site: 32007
Anderlecht
Site: 32013
Deurne
Site: 32009
Edegem
Site: 32003
Ghent
Site: 32005
Ghent
Site: 32015
Kortrijk
Site: 32008
Liège
Site: 32014
Roeselare
Ireland8 sites
Site: 35303
Cork
Site: 35301
Dublin
Site: 35309
Dublin
Site: 35310
Dublin
Site: 35306
Limerick
Site: 35313
Mullingar
Site: 35304
Tralee
Site: 35305
Waterford
Romania7 sites
Site: 40016
Bucharest
Site: 40018
Bucharest
Site: 40012
Craiova
Site: 40019
Craiova
Site: 40003
Judetul Ilfov
Site: 40017
Oradea
Site: 40020
Timișoara
Slovakia7 sites
Site: 42110
Bratislava
Site: 42114
Košice
Site: 42113
Michalovce
Site: 42111
Nové Zámky
Site: 42112
Piešťany
Site: 42108
Poprad
Site: 42109
Žilina
Turkey (Türkiye)7 sites
Site: 90005
Ankara
Site: 90008
Ankara
Site: 90002
Izmir
Site: 90003
Izmir
Site: 90007
Kocaeli
Site: 90004
Manisa
Site: 90006
Sivas
Israel6 sites
Site: 97201
Haifa
Site: 97202
Jerusalem
Site: 97207
Kfar Saba
Site: 97203
Petah Tikva
Site: 97205
Petah Tikva
Site: 97206
Tel HaShomer
Italy6 sites
Site: 39007
Avellino
Site: 39002
Cantanzaro
Site: 39010
Florence
Site: 39006
Perugia
Site: 39013
Treviglio (BG)
Site: 39009
Varese
Poland6 sites
Site: 48002
Kolbuszowa Dolna
Site: 48006
Krakow
Site: 48010
Lublin
Site: 48005
Piaseczno
Site: 48001
Warsaw
Site: 48008
Warsaw
Portugal6 sites
Site: 35104
Lisbon
Site: 35105
Lisbon
Site: 35102
Matosinhos Municipality
Site: 35103
Porto
Site: 35101
Setúbal
Site: 35106
Tomar
Sweden6 sites
Site: 46004
Halmstad
Site: 46013
Lund
Site: 46014
Norrtälje
Site: 46001
Stockholm
Site: 46012
Stockholm
Site: 46015
Umeå
Hungary5 sites
Site: 36003
Csongrád
Site: 36011
Hajdúszoboszló
Site: 36002
Nyíregyháza
Site: 36008
Salgótarján
Site: 36009
Szekszárd
Denmark4 sites
Site: 45008
Aarhus N
Site: 45003
Frederiksberg
Site: 45009
Herlev
Site: 45011
Odense C
Slovenia4 sites
Site: 38601
Ljubljana
Site: 38606
Maribor
Site: 38607
Maribor
Site: 38610
Ptuj
Australia3 sites
Site: 61006
Adelaide
Site: 61001
Kogarah, Sydney
Site: 61016
Victoria
About this study
Official title: A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
- Being tested
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo
- Keywords
- Vesitrim, Betanis, Urgency, Frequency, Mirabegron, YM178, Betmiga, Vesicare, Micturition, YM905, Solifenacin, Urinary incontinence, Overactive Bladder (OAB), Myrbetriq, Vesikur, Urgency incontinence
- Medical subject headings
- Urinary Bladder Diseases, Urinary Bladder, Overactive, Urologic Diseases, Urinary Incontinence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mirabegron 25 mgDrug
Also called Betmiga, Myrbetriq, YM178, Betanis
Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
mirabegron 50 mgDrug
Also called YM905, Vesitrim, Vesikur, Vesicare
Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
solifenacin 5 mgDrug
Also called Vesicare, Vesitrim, YM905, Vesikur
Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
solifenacin 10 mgDrug
Also called Vesicare, Vesitrim, YM905, Vesikur
Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
mirabegron 25 mg matching placeboDrug
Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
mirabegron 50 mg matching placeboDrug
Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
solifenacin 5 mg matching placeboDrug
Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
solifenacin 10 mg matching placeboDrug
Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
| Study group | Role | What they receive |
|---|---|---|
| Combination (solifenacin + mirabegron) | Experimental | Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period. Receives: Drug: mirabegron 25 mg; Drug: mirabegron 50 mg; Drug: solifenacin 5 mg; Drug: solifenacin 10 mg matching placebo |
| Solifenacin 5 mg | Active comparator | Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period Receives: Drug: solifenacin 5 mg; Drug: mirabegron 25 mg matching placebo; Drug: mirabegron 50 mg matching placebo; Drug: solifenacin 10 mg matching placebo |
| Solifenacin 10 mg | Active comparator | Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period. Receives: Drug: solifenacin 10 mg; Drug: mirabegron 25 mg matching placebo; Drug: mirabegron 50 mg matching placebo; Drug: solifenacin 5 mg matching placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
The mean number of incontinence episodes (complaint of any involuntary leakage of urine) per day was derived from number of incontinence episodes recorded on valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period. The analysis population consisted of the Full Analysis Set (FAS) which comprised of all the Randomized Analysis Set's (RAS) participants who met the following criteria: took at least 1 dose of double-blind study drug after randomization, reported at least 1 micturition in the baseline diary \& at least 1 micturition postbaseline \& reported at least 1 incontinence episode in the baseline diary. For participants who withdrew before EoT (week 12) and have no measurement available for that diary period, the Last Observation Carried Forward (LOCF) value during the double-blind study period was used as EoT value to derive the primary variable.
Measured: Baseline and end of treatment (up to 12 weeks)
Secondary outcomes (35)
Change From Baseline to Weeks 4, 8 & 12 in Mean Number of Incontinence Episodes Per 24 Hours
The mean number of incontinence episodes (complaint of any involuntary leakage of urine) per day was derived from number of incontinence episodes recorded on valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period.
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in Mean Number of Micturitions Per 24 Hours
The average number of micturitions (voluntary urinations (excluding incontinence only episodes)) per 24 hours was derived from number of micturitions recorded on valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period (excluding incontinence only episodes).
Measured: Baseline and weeks 4, 8 & 12
Number of Incontinence Episodes Reported During the 3-Day Diary
The number of incontinence episodes (complaint of any involuntary leakage of urine) per day was derived from total number of incontinence episodes on valid diary days recorded during the 3-day micturition diary period.
Measured: Weeks 4, 8 and 12
Change From Baseline in Mean Volume Voided (MVV) Per Micturition
MVV per micturition was defined as MVV (mL) per micturition during last 3 days of the 3-day micturition diary period. MVV per micturition was calculated as the sum of each volume voided for each record with volume voided > 0 on valid diary days divided by the total number of records with a volume voided > 0 on valid diary days during the 3-day micturition diary period.
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline to EoT in Corrected Micturition Frequency (CMF)
CMF was defined as the mean number of micturitions per 24 hours that participants would have at EoT if their fluid intake had remained unchanged since baseline. This was calculated by the MVV per Micturition at baseline multiplied by the mean number of micturitions per 24 hours at baseline divided by the MVV per micturition at EoT.
Measured: Baseline and EoT (up to 12 weeks)
Change From Baseline in Mean Number of Urgency Incontinence (UI) Episodes Per 24 Hours
UI was defined as the complaint of involuntary urine leakage accompanied by or immediately preceded by urgency. UI was measured using the Patient Perception of Intensity of Urgency Scale (PPIUS), a patient reported outcome validated 5-point categorical scale rating the degree of associated urinary urgency severity (0=No urgency, I felt no need to empty my bladder, but did so for other reasons. 1=Mild, I could postpone voiding as long as necessary, without fear of wetting myself. 2= Moderate, I could postpone voiding for a short while, without fear of wetting myself. 3=Severe, I could not postpone voiding, but had to rush to the toilet in order not to wet myself. 4=Urgency incontinence, I leaked before arriving to the toilet). One urgency incontinence episode was counted for each record of the diary in which the following occurred: incontinence episode or 'both' was recorded \& severity of urinary urgency recorded was 3 or 4.
Measured: Baseline and weeks 4, 8 & 12
Number of UI Episodes Reported During the 3-Day Diary
Number of UI episodes was calculated using the number of UI episodes recorded on valid diary days during the 3-day micturition diary period. NOTE: Only urgency incontinence episodes recorded on a valid diary day were counted.
Measured: Weeks 4, 8 and 12
Change From Baseline in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
An urgency episode was defined as the complaint of a sudden, compelling desire to pass urine, which is difficult to defer. The mean number of urgency episodes (severity of 3 or 4) per 24 hours was defined as the average number of times a participant recorded an urgency episode (severity of 3 or 4) with or without incontinence per day during the 3-day micturition diary period. Measured using the PPIUS scale. This was calculated using the sum of each record with an urgency episode (severity of 3 or 4) recorded on a valid diary day divided by the number of valid diary days during the 3-day micturition diary period.
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in Mean Number of Pads Per 24 Hours
The mean number of pads per 24 hours was defined as the average number of times a participant recorded a new pad used per day during the 3-day micturition diary period. This was calculated using the number of new pads used during valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period.
Measured: Baseline and weeks 4, 8 & 12
Number of Pads Used During the 3-Day Diary
The number of pads used was defined as the number of times a participant recorded a new pad used during the 3-day micturition diary period. This was calculated using the sum of each record with new pad checked. Only records with new pad checked on a valid diary day were counted.
Measured: Weeks 4, 8 and 12
Change From Baseline in Mean Number of Nocturia Episodes
Mean number of nocturia episodes was defined as the number of times a participant urinated (excluding incontinence only episodes) while sleeping during the 3-day diary period, divided by the number of valid diary days during the diary period. Night time episode of incontinence only was not considered a nocturia episode. Nocturia episodes were counted for each micturition record which occurred between the date/time of going to bed with intention to sleep and the date/time of getting up with intention to stay awake on a valid diary day \& which was accompanied by a sleep interruption. Nocturia only determined for those who were not night-shift workers.
Measured: Baseline and weeks 4, 8 & 12
Number of Nocturia Episodes Reported Over 3-Day Diary
The number of nocturia episodes was defined as the number of times a participant urinated (excluding incontinence only episodes) during sleeping time during the 3-day micturition diary period. This was calculated using the sum of each nocturia episode recorded on valid diary days during the 3-day micturition diary period.
Measured: Weeks 4, 8 and 12
Number of Participants With Change From Baseline to EoT in Euroqol European Quality of Life-5 Dimensions (EQ-5D) Subscale Score: Mobility
The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.
Measured: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Self-care
The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.
Measured: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Usual Activities
The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.
Measured: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Pain/Discomfort
The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.
Measured: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Anxiety/Depression
The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.
Measured: Baseline and EoT (up to 12 weeks)
Change From Baseline in Overactive Bladder Symptom (OAB-q) Symptom Bother Score
The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). Symptom Bother score ranges from 0 (least severity) to 100 (worst severity).
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q Health-Related Quality of Life (HRQL) Total Score
The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Coping
The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Concern
The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Sleep
The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Social Interaction
The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) Score
The TS-VAS rated participant satisfaction with treatment on a scale from 0 (No, not at all) to 10 (Yes, completely).
Measured: Baseline and weeks 4, 8 & 12
Change From Baseline in Patient Perception Bladder Control (PPBC) Score
The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. PPBC score: 1-no problem, 2- some very minor problems, 3-some minor problems, 4-moderate problems, 5-severe problems, 6-many severe problems.
Measured: Baseline and weeks 4, 8 & 12
Number of Participants in Each Category of Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)
The PGIC was a 2-part questionnaire, assessing both the change in the participant's overall condition (Patient Impression in General Health (PIBS)) and change in bladder condition since the start of the study (Patient Impression in General Health (PIGH)) (from very much worse to very much improved). The CGIC was a single questionnaire assessing the participant's change in bladder condition since the beginning of the study (Clinician Impression in Bladder Symptoms (CIBS)).
Measured: End of treatment (up to 12 weeks)
Percentage of Participants With at Least a 50% Decrease From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
Incontinence was defined as any involuntary leakage of urine.
Measured: Weeks 4, 8 and 12
Percentage of Participants With Zero Incontinence Episodes Postbaseline
Incontinence was defined as any involuntary leakage of urine.
Measured: Weeks 4, 8 and 12
Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline
Micturitions were defined as voluntary urinations (excluding incontinence only episodes).
Measured: Weeks 4, 8 and 12
Percentage of Participants With at Least a 10-Point Improvement From Baseline in OAB-q Symptom Bother Score
The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). Symptom Bother score ranges from 0 (least severity) to 100 (worst severity).
Measured: Weeks 4, 8 and 12
Percentage of Participants With at Least a 10-Point Improvement From Baseline in HRQL Total Score
HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).
Measured: Weeks 4, 8 and 12
Percentage of Participants With at Least a 1-Point Improvement From Baseline in PPBC
The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition.
Measured: Weeks 4, 8 and 12
Percentage of Participants With Major (at Least 2-Point) Improvement From Baseline in PPBC
The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition.
Measured: Weeks 4, 8 and 12
Number of Participants With Adverse Events (AEs)
AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures \& which does not necessarily have a causal relationship with this treatment. Treatment-Emergent Adverse Event (TEAE) referred to an adverse event which started or worsened in the period from first double-blind medication intake until 30 days after the last double-blind medication intake.
Measured: From first dose of double blind treatment until 30 days after last dose (up to 16 weeks)
Change From Baseline in Post Void Residual (PVR) Volume
PVR Volume was assessed by bladder scan.
Measured: Baseline and weeks 4, 8 & 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jul 2013 (estimated)
- Study start10 Jul 2013
- Primary completion24 Nov 2014
- Study completion25 Nov 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Urinary Bladder DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 2,174 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Study Manager, Study director, Astellas Pharma Europe Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01908829
- Sponsor's protocol ID
- 905-EC-012
- Other IDs
- 2012-005401-41
- Acronym
- BESIDE
- Status last verified
- Oct 2024
- First submitted
- 24 Jul 2013
- Last updated
- 31 Oct 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Publications
Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stolzel M, Choudhury N, Drake MJ. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus. 2017 Dec;3(6):629-638. doi: 10.1016/j.euf.2017.08.008. Epub 2017 Sep 12.
PubMed 28916436Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stolzel M, Herholdt C, MacDiarmid S; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8.
PubMed 26965560
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms
- ClinicalTrials.gov ID
- NCT01908829
- Acronym / sponsor ID
- BESIDE / 905-EC-012
- Keywords
- Vesitrim, Betanis, Urgency, Frequency, Mirabegron, YM178, Betmiga, Vesicare
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,174 participants (actual)
- Lead sponsor
- Astellas Pharma Europe Ltd.Industry (pharma, biotech, devices)
- Study start
- 10 Jul 2013 (actual)
- Primary completion
- 24 Nov 2014 (actual)
- Study completion
- 25 Nov 2014 (actual)
- First posted
- 26 Jul 2013 (estimated)
- Results
- Posted 9 Oct 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Combination (solifenacin + mirabegron) | Experimental | Drug: mirabegron 25 mg, Drug: mirabegron 50 mg, Drug: solifenacin 5 mg, Drug: solifenacin 10 mg matching placeboParticipants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period. |
| Solifenacin 5 mg | Active comparator | Drug: solifenacin 5 mg, Drug: mirabegron 25 mg matching placebo, Drug: mirabegron 50 mg matching placebo, Drug: solifenacin 10 mg matching placeboParticipants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period |
| Solifenacin 10 mg | Active comparator | Drug: solifenacin 10 mg, Drug: mirabegron 25 mg matching placebo, Drug: mirabegron 50 mg matching placebo, Drug: solifenacin 5 mg matching placeboParticipants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Main Inclusion at Screening:
- Main Inclusion at Run-in (Visit 2):
- Main Inclusion at Randomization (Visit 3):
Key exclusion criteria (20 listed)
- Main Exclusion at Screening:
- Main Exclusion at Randomization (visit 3):
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mirabegron 25 mgAlso: Betmiga, Myrbetriq, YM178, BetanisMirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food. | Drug | Combination (solifenacin + mirabegron) |
| mirabegron 50 mgAlso: YM905, Vesitrim, Vesikur, VesicareMirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food. | Drug | Combination (solifenacin + mirabegron) |
| solifenacin 5 mgAlso: Vesicare, Vesitrim, YM905, VesikurSolifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food. | Drug | Combination (solifenacin + mirabegron), Solifenacin 5 mg |
| solifenacin 10 mgAlso: Vesicare, Vesitrim, YM905, VesikurSolifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food. | Drug | Solifenacin 10 mg |
| mirabegron 25 mg matching placeboMatching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food. | Drug | Solifenacin 10 mg, Solifenacin 5 mg |
| mirabegron 50 mg matching placeboMatching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food. | Drug | Solifenacin 10 mg, Solifenacin 5 mg |
| solifenacin 5 mg matching placeboMatching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food. | Drug | Solifenacin 10 mg |
| solifenacin 10 mg matching placeboMatching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food. | Drug | Combination (solifenacin + mirabegron), Solifenacin 5 mg |
Primary outcome
Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
Time frame: Baseline and end of treatment (up to 12 weeks)
The mean number of incontinence episodes (complaint of any involuntary leakage of urine) per day was derived from number of incontinence episodes recorded on valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period. The analysis population consisted of the Full Analysis Set (FAS) which comprised of all the Randomized Analysis Set's (RAS) participants who met the following criteria: took at least 1 dose of double-blind study drug after randomization, reported at least 1 micturition in the baseline diary \& at least 1 micturition postbaseline \& reported at least 1 incontinence episode in the baseline diary. For participants who withdrew before EoT (week 12) and have no measurement available for that diary period, the Last Observation Carried Forward (LOCF) value during the double-blind study period was used as EoT value to derive the primary variable.
35 secondary outcomes
Change From Baseline to Weeks 4, 8 & 12 in Mean Number of Incontinence Episodes Per 24 Hours
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in Mean Number of Micturitions Per 24 Hours
Time frame: Baseline and weeks 4, 8 & 12
Number of Incontinence Episodes Reported During the 3-Day Diary
Time frame: Weeks 4, 8 and 12
Change From Baseline in Mean Volume Voided (MVV) Per Micturition
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline to EoT in Corrected Micturition Frequency (CMF)
Time frame: Baseline and EoT (up to 12 weeks)
Change From Baseline in Mean Number of Urgency Incontinence (UI) Episodes Per 24 Hours
Time frame: Baseline and weeks 4, 8 & 12
Number of UI Episodes Reported During the 3-Day Diary
Time frame: Weeks 4, 8 and 12
Change From Baseline in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in Mean Number of Pads Per 24 Hours
Time frame: Baseline and weeks 4, 8 & 12
Number of Pads Used During the 3-Day Diary
Time frame: Weeks 4, 8 and 12
Change From Baseline in Mean Number of Nocturia Episodes
Time frame: Baseline and weeks 4, 8 & 12
Number of Nocturia Episodes Reported Over 3-Day Diary
Time frame: Weeks 4, 8 and 12
Number of Participants With Change From Baseline to EoT in Euroqol European Quality of Life-5 Dimensions (EQ-5D) Subscale Score: Mobility
Time frame: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Self-care
Time frame: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Usual Activities
Time frame: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Pain/Discomfort
Time frame: Baseline and EoT (up to 12 weeks)
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Anxiety/Depression
Time frame: Baseline and EoT (up to 12 weeks)
Change From Baseline in Overactive Bladder Symptom (OAB-q) Symptom Bother Score
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q Health-Related Quality of Life (HRQL) Total Score
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Coping
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Concern
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Sleep
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in OAB-q HRQL Subscale Score: Social Interaction
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) Score
Time frame: Baseline and weeks 4, 8 & 12
Change From Baseline in Patient Perception Bladder Control (PPBC) Score
Time frame: Baseline and weeks 4, 8 & 12
Number of Participants in Each Category of Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)
Time frame: End of treatment (up to 12 weeks)
Percentage of Participants With at Least a 50% Decrease From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
Time frame: Weeks 4, 8 and 12
Percentage of Participants With Zero Incontinence Episodes Postbaseline
Time frame: Weeks 4, 8 and 12
Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline
Time frame: Weeks 4, 8 and 12
Percentage of Participants With at Least a 10-Point Improvement From Baseline in OAB-q Symptom Bother Score
Time frame: Weeks 4, 8 and 12
Percentage of Participants With at Least a 10-Point Improvement From Baseline in HRQL Total Score
Time frame: Weeks 4, 8 and 12
Percentage of Participants With at Least a 1-Point Improvement From Baseline in PPBC
Time frame: Weeks 4, 8 and 12
Percentage of Participants With Major (at Least 2-Point) Improvement From Baseline in PPBC
Time frame: Weeks 4, 8 and 12
Number of Participants With Adverse Events (AEs)
Time frame: From first dose of double blind treatment until 30 days after last dose (up to 16 weeks)
Change From Baseline in Post Void Residual (PVR) Volume
Time frame: Baseline and weeks 4, 8 & 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 28916436Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stolzel M, Choudhury N, Drake MJ. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus. 2017 Dec;3(6):629-638. doi: 10.1016/j.euf.2017.08.008. Epub 2017 Sep 12.
- Derived from this study: PubMed 26965560Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stolzel M, Herholdt C, MacDiarmid S; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8.
- Individual participant dataSharing planned: Yes. Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Related trials for Urinary Bladder Diseases
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
RecruitingPhase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Bladder Cancer
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Study Manager study director
Astellas Pharma Europe Ltd.
219 sites in 31 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing mirabegron 25 mg, mirabegron 50 mg and solifenacin 5 mg in people with Urinary Bladder Diseases and Urinary Bladder Overactive, run by Astellas Pharma Europe Ltd. at 219 sites in 31 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 219 sites in United States, Russia, Canada, Spain, United Kingdom and 26 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Oct 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours (time frame: Baseline and end of treatment (up to 12 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01908829, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.